IFRD1

Across TCGA pan-cancer cohorts, IFRD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IFRD1 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IFRD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IFRD1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, GBM, and LSCC are the cancer types where IFRD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.405	0.856	.005	14	view →
GBM	OS	Tertile	All	0.254	0.512	.029	10	view →
LSCC	DFS	Tertile	II,III,IV	0.856	0.497	.007	9	view →
LUAD	DFS	Median	III,IV	0.776	0.400	.009	7	view →
CCRCC	DFS	Median	All	0.632	1.000	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IFRD1–PDAC (OS)

Open the PDAC breakdown →